



## Provider Alert

### The Oral Oncology Split Fill Program From Optum Specialty Pharmacy

The Oral Oncology Split Fill Program from Optum Specialty Pharmacy is a new program that aims to improve the member experience while decreasing medication waste. The program is for patients new to therapy with medications that have a high discontinuation rate due to adverse effects.

Here's how it works:

- Optum reaches out to the member once they receive a prescription.
- Members receive a two-week supply of the prescribed medication twice a month instead of a full 30-day supply once a month.
- Before the renewal, Optum will check with the members to make sure they're tolerating the medication.
- If the member experiences an adverse reaction, the clinical team will work with them and contact the prescriber when needed.
- After six fills or three months of therapy, members who are tolerating the medication will receive the standard 30-day supply for as long they continue therapy.

By decreasing the amount dispensed for the first six fills, the program can result in early identification of adverse events and timely clinical intervention and adherence monitoring.

#### Which Medications Are In-Scope

The following oral oncology medications are currently included in this program:

- Abiraterone
- Afinitor
- Afinitor Disperz
- Bexarotene
- Bosulif
- Cabometyx
- Daurismo
- Erivedge
- Erlotinib
- Everolimus
- Inlyta
- Inrebic
- Lorbrena
- Nexavar
- Nubeqa
- Odomzo
- Retevmo
- Rozlytrek
- Sorafenib
- Sprycel
- Talzenna
- Tarceva
- Targretin
- Verzenio
- Vizimpro
- Votrient
- Xalkori
- Xtandi
- Zolanza
- Zykadia
- Zytiga





## Provider Alert

### How Optum Specialty Pharmacy Supports Your Patients

Optum aims to improve the member experience throughout the process in several ways:

- Validating the prescription is for the first fill for the member and a medication in the program
- Advising the member about the partial fill program and what to expect based upon their tolerance to this therapy
- Connecting the member directly with a pharmacist for the initial consult
- Asking the member questions during the refill call to determine their compliance and tolerance
- Connecting the member to an Optum pharmacist for further discussion and a clinical intervention as needed

### How to Take The Next Steps

As the prescriber, you don't need to take any action. You can continue writing the prescriptions as you normally would. Optum will contact you by phone if adverse events or adherence issues are identified with your patient.

#### We're Here to Help

If you have questions, please contact Optum at 855-427-4682. Thank you.